drugset / Trial / NCT00691405

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00691405

Phase 2 Completed 215 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.

Timeline

Start
2003-10
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 5 ug Inhaled
Subject Arformoterol Small molecule 15 ug Inhaled
Subject Arformoterol Small molecule 25 ug Inhaled
Subject Arformoterol Small molecule 50 ug Inhaled